Co-enzyme Q-10 Supplementation on Serum Anti-Müllerian Hormone Levels in Young Infertile Women with Diminished Ovarian Reserve: A Dose- Response Study

Abstract

A quasi-experimental study was conducted at the Reproductive Endocrinology and Infertility Unit (under the Department of Obstetrics & Gynaecology) of Dhaka Medical College Hospital, Dhaka, Bangladesh, between January and December of 2022, to evaluate the effect of two different doses of co-enzyme Q10 on serum anti-Müllerian hormone (AMH) levels in young infertile women with diminished ovarian reserve. A total of 76 infertile women aged between 18 and 35 years with serum AMH <1.2 ng/ml were enrolled in this study. Participants were allocated into two groups: group A received CoQ10 100 mg three times daily for two months, while group B received CoQ10 200 mg three times daily for the same duration. Serum AMH levels were measured before and after treatment. Baseline characteristics and pre-treatment AMH levels were comparable between the groups. Although the serum AMH increased significantly in both groups after treatment (p<0.001), the mean increase in AMH was significantly higher in group B compared to group A (1.32±0.96 ng/ml vs. 0.48±0.47 ng/ml; p<0.001). Post-treatment AMH levels were also significantly higher in group B than group A (1.93±1.02 ng/ml vs. 1.09±0.65 ng/ml; p<0.001). No serious adverse effect was reported in either group. Our data suggests that co-enzyme Q10 supplementation significantly increases serum AMH levels in young infertile women with diminished ovarian reserve and the 200 mg regimen was more effective than 100 mg regimen.

International Journal of Human and Health Sciences Vol. 10 No. 03 Jul’26 Page: 148-152